Blueprint Medicines(BPMC) - 2024 Q3 - Quarterly Results

EXHIBIT 99.1 Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance -- Achieved $128.2 million in AYVAKIT net product revenues in the third quarter 2024 -- -- Raising AYVAKIT net product revenue guidance to $475 million to $480 million for 2024 -- -- On track to initiate the registration-enabling HARBOR Part 2 study of elenestinib in ISM by year end -- CAMBRIDGE, Mass., October 30, 2024 – Blueprint Medicines Corporation (Nasdaq: BPMC) tod ...